Efficacy and safety of glycyrrhizic acid preparation treating comorbid liver injury in COVID-19: A systematic review
Background: No specific drug for COVID-19 has been found, and many studies have found that different degrees of liver injury often occurred after infection with COVID-19. Glycyrrhizic acid preparation (GAP) has been frequently used clinically, often combined with conventional treatments such as anti...
Main Authors: | Xu Liu, Xia Tian, Zhipeng Ma, Jiali Chen, Qingsong Huang, Peiyang Gao, Chuantao Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-11-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1003697/full |
Similar Items
-
Effect of Glycyrrhizic Acid on Scopolamine-Induced Cognitive Impairment in Mice
by: Ju Yeon Ban, et al.
Published: (2020-05-01) -
Glycyrrhizic acid improving the liver protective effect by restoring the composition of Lactobacillus
by: Tianjie Yuan, et al.
Published: (2019-01-01) -
Glycyrrhizic acid glycosides reduces extensive tripterygium glycosides-induced lipid deposition in hepatocytes
by: Yifei Yang, et al.
Published: (2023-07-01) -
Glycyrrhizic Acid and Its Hydrolyzed Metabolite 18β-Glycyrrhetinic Acid as Specific Ligands for Targeting Nanosystems in the Treatment of Liver Cancer
by: Luciano A. Stecanella, et al.
Published: (2021-10-01) -
Transcriptome and Lipid Metabolomics-Based Discovery: Glycyrrhizic Acid Alleviates Tripterygium Glycoside Tablet-Induced Acute Liver Injury by Regulating the Activities of CYP and the Metabolism of Phosphoglycerides
by: Qiaoli Shi, et al.
Published: (2022-02-01)